Reslizumab

Products

Reslizumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Cinqaero).

Structure and properties

Reslizumab is a humanized IgG4/κ monoclonal antibody produced by biotechnological methods. The molecular mass is approximately 147 kDa.

Effects

Reslizumab (ATC R03DX08) binds with high affinity to interleukin-5 (IL-5) and inhibits interaction with its receptor on the cell surface of eosinophils. IL-5 is a cytokine responsible for eosinophil growth, differentiation, recruitment, activation and survival. By binding the antibody to IL-5, reslizumab inhibits these effects and has an anti-inflammatory effect. The half-life is 24 days.

Indications

For adjunctive treatment of eosinophilic asthma.

Dosage

According to the SmPC. The drug is usually administered as an intravenous infusion every four weeks.

Contraindications

  • Hypersensitivity

For complete precautions, see the drug label.

Interactions

Complete data on drug-drug interactions are not available.

Adverse effects

The most common potential adverse effect in clinical trials was an increase in blood creatine phosphokinase. Reslizumab may cause hypersensitivity reactions.